IPP Bureau
Onchilles Pharma gets FDA green light for first-in-human trials of breakthrough cancer therapy
By IPP Bureau - February 04, 2026
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
Pfizer’s monthly obesity drug shows breakthrough weight loss in Phase 2b trial
By IPP Bureau - February 04, 2026
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
Cirena launches to revolutionize long RNA production for CRISPR & gene editing
By IPP Bureau - February 04, 2026
As CRISPR and prime editing applications advance, researchers increasingly rely on longer guide RNAs to boost editing efficiency and reduce off-target effects
Epigenica launches EpiFinder Analysis Service to accelerate Epigenomic research
By IPP Bureau - February 04, 2026
The new service delivers end-to-end support, managing every stage of an epigenomics project
China nod to Darolutamide for metastatic hormone-sensitive prostate cancer
By IPP Bureau - February 04, 2026
The approval follows the pivotal Phase III ARANOTE trial, which demonstrated that darolutamide plus ADT cut the risk of radiological progression or death by 46% compared to placebo plus ADT
India’s silent oral cancer crisis: Early detection could save thousands
By IPP Bureau - February 04, 2026
SPARC announces receipt of priority review voucher associated with Sezaby approval
By IPP Bureau - February 04, 2026
A PRV is a tradable voucher granted by the FDA to encourage the development of new treatments for rare pediatric diseases
Wanbury achieves first sales invoicing and commercial shipment milestone
By IPP Bureau - February 04, 2026
This achievement validates global demand and catapults Wanbury into high-growth acceleration
Zydus Wellness net sales up by 113.7% in Q3 FY26
By IPP Bureau - February 04, 2026
Glucon-D maintained its leadership position with a 59% MAT market share
NATCO receives FDA's tentative approval for Erdafitinib tablets
By IPP Bureau - February 04, 2026
NATCO’s Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alteration
Lupin launches Dasatinib tablets in US, eyes $930 million oncology market
By IPP Bureau - February 03, 2026
Artemis Medicare reports strong Q3 growth: revenue up 17%, net profit up 8%
By IPP Bureau - February 03, 2026
Nine-month revenue grew 17.5% to Rs 76,277 lakh, EBITDA climbed to Rs 15,981 lakh, and net profit reached Rs 8,200 lakh
Lupin & TB Alliance team up to push groundbreaking TB drug forward
By IPP Bureau - February 03, 2026
TB Alliance will continue to lead clinical development, while Lupin will leverage its global manufacturing, regulatory, and supply chain expertise to ensure the drug reaches patients worldwide
Dr. David Berman to Join Moderna as Chief Development Officer
By IPP Bureau - February 02, 2026
Over a two-decade career, Dr. Berman has worked on more than a dozen clinical-stage immunotherapies, including senior leadership roles in developing four oncology biologics
Hester Biosciences posts strong Q3 profit surge as poultry business powers growth
By IPP Bureau - February 02, 2026
The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period
